Search Results - "Vidriales, Maria Belén"

The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells by LOPEZ-CORRAL, Lucia, GUTIERREZ, Norma C, VIDRIALES, Maria Belén, MATEOS, Maria Victoria, RASILLO, Ana, GARCIA-SANZ, Ramón, PAIVA, Bruno, SAN MIGUEL, Jesus F

“…Genetic aberrations detected in multiple myeloma (MM) have also been reported in the premalignant conditions monoclonal gammopathy of undetermined significance…”
Get full text

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy by MATEO, Gema, MONTALBDN, M. Angeles, DE LA RUBIA, Javier, DIAZ-MEDIAVILLA, Joaquin, SUREDA, Anna, RIBERA, José M, OJANGUREN, José M, DE ARRIBA, Felipe, PALOMERA, Luis, TEROL, Maria J, ORFAO, Alberto, SAN MIGUEL, Jesus F, VIDRIALES, Maria-Belen, LAHUERTA, Juan J, MATEOS, Maria V, GUTIERREZ, Norma, ROSINOL, Laura, MONTEJANO, Laura, BLADE, Joan, MARTINEZ, Rafael

“…To analyze the prognostic impact of immunophenotyping in patients with multiple myeloma (MM). We have prospectively analyzed the prognostic impact of antigenic…”
Get full text

Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients by PAIVA, Bruno, VIDRIALES, Maria-Belén, PEREZ, Jose J, MATEO, Gema, MONTALBAN, Maria Angeles, MATEOS, Maria Victoria, BLADE, Joan, LAHUERTA, Juan José, ORFAO, Alberto, SAN MIGUEL, Jesús F

“…Quantification of bone marrow plasma cells in multiple myeloma patients using conventional morphology is of limited prognostic value, while the merit of…”
Get full text

The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients by Paiva, Bruno, Vidriales, Maria-Belén, Mateo, Gema, Pérez, Jose J., Montalbán, Maria Angeles, Sureda, Anna, Montejano, Laura, Gutiérrez, Norma C., García de Coca, Alfonso, de las Heras, Natalia, Mateos, Maria Victoria, López-Berges, Maria Consuelo, García-Boyero, Raimundo, Galende, Josefina, Hernández, Jose, Palomera, Luis, Carrera, Dolores, Martínez, Rafael, de la Rubia, Javier, Martín, Alejandro, González, Yolanda, Bladé, Joan, Lahuerta, Juan José, Orfao, Alberto, San-Miguel, Jesús F., on behalf of the GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups

“…Multiparameter flow cytometry immunophenotyping allows discrimination between normal (N-) and myelomatous (MM-) plasma cells (PCs) within the bone marrow…”
Get full text

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype by Colado, Enrique, Alvarez-Fernandez, Stela, Maiso, Patricia, Martin-Sanchez, Jesus, Vidriales, Maria Belen, Garayoa, Mercedes, Ocio, Enrique M, Montero, Juan Carlos, Pandiella, Atanasio, San Miguel, Jesus F

“…1 Department of Hematology, Hospital Universitario de Salamanca, Salamanca and 2 Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca,…”
Get full text

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials by Lahuerta, Juan-Jose, Paiva, Bruno, Vidriales, Maria-Belen, Cordón, Lourdes, Cedena, Maria-Teresa, Puig, Noemi, Martinez-Lopez, Joaquin, Rosiñol, Laura, Gutierrez, Norma C, Martín-Ramos, María-Luisa, Oriol, Albert, Teruel, Ana-Isabel, Echeveste, María-Asunción, de Paz, Raquel, de Arriba, Felipe, Hernandez, Miguel T, Palomera, Luis, Martinez, Rafael, Martin, Alejandro, Alegre, Adrian, De la Rubia, Javier, Orfao, Alberto, Mateos, María-Victoria, Blade, Joan, San-Miguel, Jesus F

“…Purpose To perform a critical analysis on the impact of depth of response in newly diagnosed multiple myeloma (MM). Patients and Methods Data were analyzed…”
Get full text

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma by Goicoechea, Ibai, Puig, Noemi, Cedena, Maria-Teresa, Burgos, Leire, Cordón, Lourdes, Vidriales, María-Belén, Flores-Montero, Juan, Gutierrez, Norma C., Calasanz, Maria-Jose, Ramos, Maria-Luisa Martin, Lara-Astiaso, David, Vilas-Zornoza, Amaia, Alignani, Diego, Rodriguez, Idoia, Sarvide, Sarai, Alameda, Daniel, Garcés, Juan José, Rodriguez, Sara, Fresquet, Vicente, Celay, Jon, Garcia-Sanz, Ramón, Martinez-Lopez, Joaquin, Oriol, Albert, Rios, Rafael, Martin-Sanchez, Jesus, Martinez-Martinez, Rafael, Sarra, Josep, Hernandez, Miguel-Teodoro, de la Rubia, Javier, Krsnik, Isabel, Moraleda, Jose-Maria, Palomera, Luis, Bargay, Joan, Martinez-Climent, Jose-Angel, Orfao, Alberto, Rosiñol, Laura, Mateos, Maria-Victoria, Lahuerta, Juan-José, Blade, Joan, San Miguel, Jesús, Paiva, Bruno

“…Patients with multiple myeloma (MM) carrying standard- or high-risk cytogenetic abnormalities (CAs) achieve similar complete response (CR) rates, but the later…”
Get full text

Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma by Flores-Montero, Juan, de Tute, Ruth, Paiva, Bruno, Perez, José Juan, Böttcher, Sebastian, Wind, Henk, Sanoja, Luzalba, Puig, Noemí, Lecrevisse, Quentin, Vidriales, María Belén, van Dongen, Jacques J. M., Orfao, Alberto

“…In recent years, several studies on large series of multiple myeloma (MM) patients have demonstrated the clinical utility of flow cytometry monitoring of…”
Get full text

Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile by Paiva, Bruno, Paino, Teresa, Sayagues, Jose-Maria, Garayoa, Mercedes, San-Segundo, Laura, Martín, Montserrat, Mota, Ines, Sanchez, María-Luz, Bárcena, Paloma, Aires-Mejia, Irene, Corchete, Luis, Jimenez, Cristina, Garcia-Sanz, Ramon, Gutierrez, Norma C., Ocio, Enrique M., Mateos, Maria-Victoria, Vidriales, Maria-Belen, Orfao, Alberto, San Miguel, Jesús F.

“…Circulating myeloma tumor cells (CTCs) as defined by the presence of peripheral blood (PB) clonal plasma cells (PCs) are a powerful prognostic marker in…”
Get full text

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells by Pérez-Persona, Ernesto, Vidriales, María-Belén, Mateo, Gema, García-Sanz, Ramón, Mateos, Maria-Victoria, de Coca, Alfonso García, Galende, Josefina, Martín-Nuñez, Guillermo, Alonso, José M., de las Heras, Natalia, Hernández, José M., Martín, Alejandro, López-Berges, Consuelo, Orfao, Alberto, San Miguel, Jesús F.

“…Monoclonal gammopathy of uncertain significance (MGUS) and smoldering multiple myeloma (SMM) are plasma cell disorders with a risk of progression of…”
Get full text

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance by Paiva, Bruno, Corchete, Luis A., Vidriales, Maria-Belen, Puig, Noemi, Maiso, Patricia, Rodriguez, Idoia, Alignani, Diego, Burgos, Leire, Sanchez, Maria-Luz, Barcena, Paloma, Echeveste, Maria-Asuncion, Hernandez, Miguel T., García-Sanz, Ramón, Ocio, Enrique M., Oriol, Albert, Gironella, Mercedes, Palomera, Luis, De Arriba, Felipe, Gonzalez, Yolanda, Johnson, Sarah K., Epstein, Joshua, Barlogie, Bart, Lahuerta, Juan José, Blade, Joan, Orfao, Alberto, Mateos, María-Victoria, San Miguel, Jesús F.

“…Persistence of chemoresistant minimal residual disease (MRD) plasma cells (PCs) is associated with inferior survival in multiple myeloma (MM). Thus,…”
Get full text

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma by PAIVA, Bruno, MARTINEZ-LOPEZ, Joaquin, LARANA, José-Garcia, BENGOECHEA, Enrique, MARTIN, Alejandro, DIAZ MEDIAVILLA, Joaquin, PALOMERA, Luis, DE ARRIBA, Felipe, BLADE, Joan, ORFAO, Alberto, LAHUERTA, Juan-Jose, SAN MIGUEL, Jesus F, VIDRIALES, Maria-Belen, MATEOS, Maria-Victoria, MONTALBAN, Maria-Angeles, FERNANDEZ-REDONDO, Elena, ALONSO, Lourdes, ORIOL, Albert, TERUEL, Ana-Isabel, DE PAZ, Raquel

“…To investigate the impact of immunophenotypic response (IR) versus complete response (CR) and CR plus normal serum free light chain (sFLC) ratio (stringent CR)…”
Get full text

Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma by LUDWIG, Heinz, VITERBO, Luisa, ESTEVES, Graca, STOPPA, Anne Marie, ROBINSON, Don, RICCI, Deborah, CAKANA, Andrew, ENNY, Christopher, HUAIBAO FENG, DE VELDE, Helgi Van, HAROUSSEAU, Jean-Luc, GREIL, Richard, MASSZI, Tamas, SPICKA, Ivan, SHPILBERG, Ofer, HAJEK, Roman, DMOSZYNSKA, Anna, PAIVA, Bruno, VIDRIALES, María-Belén

“…Bortezomib-thalidomide-dexamethasone (VTD) is an effective induction therapy in multiple myeloma (MM). This phase II, noncomparative study sought to determine…”
Get full text

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis by Paiva, Bruno, Mateos, María Victoria, Sanchez-Abarca, Luis Ignacio, Puig, Noemi, Vidriales, María-Belén, López-Corral, Lucía, Corchete, Luis A., Hernandez, Miguel T., Bargay, Joan, de Arriba, Felipe, de la Rubia, Javier, Teruel, Ana-Isabel, Giraldo, Pilar, Rosiñol, Laura, Prosper, Felipe, Oriol, Albert, Hernández, José, Esteves, Graça, Lahuerta, Juan José, Bladé, Joan, Perez-Simon, Jose Antonio, San Miguel, Jesús F.

“…There is significant interest in immunotherapy for the treatment of high-risk smoldering multiple myeloma (SMM), but no available data on the immune status of…”
Get full text

The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy by Alonso-Álvarez, Sara, Vidriales, Maria Belén, Caballero, Maria Dolores, Blanco, Oscar, Puig, Noemí, Martin, Alejandro, Peñarrubia, Maria Jesús, Zato, Esther, Galende, Josefina, Bárez, Abelardo, Alcoceba, Miguel, Orfão, Alberto, González, Marcos, García-Sanz, Ramón

“…Prognostic factors in Hodgkin lymphoma (HL) still fail to accurately identify high-risk patients. Tumor microenvironment in HL is a current focus of research…”
Get full text

Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia by Simoes, Catia, Villar, Sara, Ariceta, Beñat, Garcés, Juan‐José, Burgos, Leire, Alignani, Diego, Sarvide, Sarai, Martínez‐Cuadrón, David, Bergua, Juan‐Miguel, Vives, Susana, Algarra, Lorenzo, Tormo, Mar, Martinez, Pilar, Serrano, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, Gil, Cristina, Lopez‐Lorenzo, Jose‐Luis, Vidriales, Maria‐Belen, Chillon, Carmen, Labrador, Jorge, Falantes, Jose‐Francisco, Sayas, María‐José, Ayala, Rosa, Martinez‐Lopez, Joaquin, Pierola, Ana Alfonso, Calasanz, Maria‐Jose, Prosper, Felipe, San‐Miguel, Jesús F., Sanz, Miguel Á., Paiva, Bruno, Montesinos, Pau

Get full text

Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma by Paiva, Bruno, Chandia, Mauricio, Vidriales, Maria-Belen, Colado, Enrique, Caballero-Velázquez, Teresa, Escalante, Fernando, Garcia de Coca, Alfonso, Montes, Maria-Carmen, Garcia-Sanz, Ramon, Ocio, Enrique M., Mateos, Maria-Victoria, San Miguel, Jesus F.

“…Solitary plasmacytoma represents a heterogeneous group of patients; approximately half develop multiple myeloma (MM) in 2 or 3 years, whereas others remain…”
Get full text

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up by Ludwig, Heinz, Greil, Richard, Masszi, Tamas, Spicka, Ivan, Shpilberg, Ofer, Hajek, Roman, Dmoszynska, Anna, Paiva, Bruno, Vidriales, María‐Belén, Esteves, Graca, Stoppa, Anne Marie, Robinson, Don, Chaturvedi, Shalini, Ataman, Ozlem, Enny, Christopher, Feng, Huaibao, Velde, Helgi, Viterbo, Luisa

“…Summary This follow‐up extension of a randomised phase II study assessed differences in long‐term outcomes between bortezomib‐thalidomide‐dexamethasone (VTD)…”
Get full text

Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells by Pérez‐Persona, Ernesto, Mateo, Gema, García‐Sanz, Ramón, Mateos, María‐Victoria, De Las Heras, Natalia, De Coca, Alfonso García, Hernández, José M., Galende, Josefina, Martín‐Nuñez, Guillermo, Bárez, Abelardo, Alonso, José M., Martín, Alejandro, López‐Berges, Consuelo, Orfao, Alberto, San Miguel, Jesús F., Vidriales, María‐Belén

“…Summary The present study explored the impact of two novel criteria; having >95% abnormal plasma cells by flow cytometry at diagnosis and the evolving subtype…”
Get full text

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis by Puig, Noemi, Paiva, Bruno, Lasa, Marta, Burgos, Leire, Perez, Jose J., Merino, Juana, Moreno, Cristina, Vidriales, Maria-Belen, Toboso, Dolores Gómez, Cedena, Maria-Teresa, Ocio, Enrique M., Lecumberri, Ramon, García de Coca, Alfonso, Labrador, Jorge, Gonzalez, Maria-Esther, Palomera, Luis, Gironella, Mercedes, Cabañas, Valentin, Casanova, Maria, Oriol, Albert, Krsnik, Isabel, Pérez-Montaña, Albert, de la Rubia, Javier, de la Puerta, Jose-Enrique, de Arriba, Felipe, Prosper, Felipe, Martinez-Lopez, Joaquin, Lecrevisse, Quentin, Verde, Javier, Mateos, Maria-Victoria, Lahuerta, Juan-Jose, Orfao, Alberto, San Miguel, Jesús F.

“…Early diagnosis and risk stratification are key to improve outcomes in light-chain (AL) amyloidosis. Here we used multidimensional-flow-cytometry (MFC) to…”
Get full text